Table 4. Estimated differences between treatment groups and placebo in physician evaluations of nausea based on available summary information for analyzed participants.
| Allocated n = 2308 | Excluded, estimated missing (%) n = 709 (31%) | Analyzed n = 1599 | reported percent improved | Absolute difference in % improved versus placebo (95% CI) | |
|---|---|---|---|---|---|
| doxylamine/pyridoxine/dicyclomine | 288 | 99 (34%) | 189 | 71 | 14 (3.8 to 24) |
| doxylamine/pyridoxine | 284 | 71 (25%) | 213 | 78 | 21 (11 to 30) |
| dicyclomine/doxylamine | 301 | 83 (28%) | 218 | 78 | 21 (11 to 30) |
| doxylamine | 287 | 78 (27%) | 209 | 77 | 20 (10 to 29) |
| dicyclomine/pyridoxine | 286 | 91 (32%) | 195 | 61 | 4 (-6 to 14) |
| pyridoxine | 290 | 99 (34%) | 191 | 66 | 9 (-1.3 to 19) |
| dicyclomine | 286 | 83 (29%) | 203 | 61 | 4 (-6 to 14) |
| placebo | 286 | 105 (37%) | 181 | 57 | - |